Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)

NCT01272908 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01272908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01272908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab Phase IIIb Open-label, Multi-centre Assessment of Safety and Effectiveness in Patients With RA Following an Inadequate Response to One Prior Anti-TNF Inhibitor (RESET)
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
July 18, 2006
Completion date
March 12, 2009
Enrollment
120 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis